SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 clinical trial results for their Duchenne Muscular Dystrophy treatment, potentially reversing a previous FDA rejection. The stock is currently halted, but the community is celebrating the news and anticipating a significant short squeeze, while also discussing buyout possibilities and criticizing those who doubted the company.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to reports of lowered AI software sales quotas, sparking concerns about AI leadership and competition from Google. The community is debating the impact on MSFT's AI strategy and its broader influence on the market, especially in relation to AI hardware players like NVDA. Some investors view this as a buying opportunity, while others express disappointment and question the company's current direction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss its recent price movements and potential involvement in acquiring Warner Bros. Discovery assets. Community members are weighing the potential impact of a WBD deal, as well as recent reports of Netflix lobbying for regulatory approval, with some suggesting that the stock is being manipulated.

$SMOL is the first memecoin with a verified OnlyFans launched on Solana via pump.fun. It follows Smol, a rescued Alabama dachshund who survived hoarding, shelter hunger, and a 5-day post-spay escape before finding her forever home. Now pampered with treats and spa days, she shares wholesome content—no adult themes, just derpy faces, snack videos, and rescue love. $SMOL aims to normalize kindness and support animal welfare through the creator economy.

Smol Fans

$SMOL is trending as community members rally around its unique narrative: a rescue dog on OnlyFans supporting other rescue animals. With comparisons to early-stage $DOGE and a focus on community-driven growth, $SMOL is gaining attention as a potential leader in the memecoin space on the Solana network. The coin's organic growth and the team's dedication are key talking points driving interest.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential implications of Marvell's acquisition of Celestial AI, a key POET customer, and the validation it provides for POET's photonic interposer technology. The community is speculating about increased demand for POET's products and potential acquisition by a larger player like Marvell or Broadcom, with some emphasizing the company's unique technology and strong cash position. Concerns remain around dilution and the company's ability to scale production.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a surge in data center demand, a Q3 earnings beat, and forward guidance exceeding expectations. The acquisition of Celestial AI for its interconnect technology is also fueling excitement, with the community discussing the strategic implications of vertical integration and potential synergies. However, some investors are wary of a potential overvaluation and are closely watching for a pullback.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors discuss its recent government contract win for autonomous border protection using drones, though some express disappointment as the stock dipped despite the positive news. The community debates whether the contract's value is already priced in, while others emphasize the long-term potential of ONDS as a key player in the growing autonomous systems and drone defense sector. Discussions also include speculation about future acquisitions and potential benefits from .16T implementation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards as investors react to news of a large share offering intended to fund the repurchase of convertible notes, with some fearing dilution. The community is debating the long-term implications of this financial move, with opinions divided on whether it's a strategic maneuver or a sign of balance sheet strain. Adding to the volatility, commentary from Jim Cramer on CNBC has further fueled debate and speculation around the stock's future.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing volatility as traders react to news of potential shifts in economic policy and the unwinding of certain trades. Community members are debating the implications of job data and potential interest rate cuts, while some express concerns about an AI bubble. Overall, the conversation revolves around uncertainty and potential market corrections amid existing economic conditions.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GTLB is trending amidst speculation of a potential acquisition by Datadog, reportedly considering a bid over $60 per share. While some investors are excited about a possible buyout, others express skepticism, citing past false rumors and questioning the long-term value. Community members are actively discussing the legitimacy of the reports and debating potential price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Behind HeartBeam's Over 40% After-Hours Surge?

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.read more...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following...

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

Equity

HeartBeam Reports Third Quarter 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for...

HeartBeam Earnings Preview

HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13...

HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a...

HeartBeam Announces Exercise and Closing of Underwriters Over-Allotment Option for Public Offering of Common Stock

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the underwriter of its previously...

HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that it has priced its public offering...

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Current Price	$0.7096
Prev Close	$0.7068
Open	$0.6803
Dividend Yield	0.00%
50-Day Moving Average	$1.54
Beta	1.13
Avg. Volume	6.45M
PE Ratio	-1.06

52-Week High	$3.48
52-Week Low	$0.54
Market Capitalization	$24.34M
EPS (Annual)	-$0.7299
Price to Book	59.80
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BEAT
HeartBeam Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc